Boston Trust Walden Corp Buys 106,114 Shares of Haemonetics Co. (NYSE:HAE)

Boston Trust Walden Corp boosted its stake in Haemonetics Co. (NYSE:HAE) by 13.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 915,722 shares of the medical instruments supplier’s stock after buying an additional 106,114 shares during the period. Boston Trust Walden Corp’s holdings in Haemonetics were worth $71,500,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of HAE. Quarry LP acquired a new stake in Haemonetics during the 2nd quarter worth approximately $39,000. Nisa Investment Advisors LLC lifted its holdings in shares of Haemonetics by 124.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 632 shares in the last quarter. KBC Group NV boosted its position in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 712 shares during the period. iSAM Funds UK Ltd bought a new position in Haemonetics during the third quarter worth about $204,000. Finally, CWC Advisors LLC. acquired a new stake in Haemonetics in the 3rd quarter worth about $231,000. 99.67% of the stock is owned by institutional investors.

Haemonetics Stock Performance

NYSE HAE opened at $68.90 on Monday. The firm’s fifty day moving average price is $78.61 and its two-hundred day moving average price is $79.07. The stock has a market cap of $3.46 billion, a PE ratio of 28.59, a PEG ratio of 1.07 and a beta of 0.39. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics Co. has a fifty-two week low of $67.26 and a fifty-two week high of $97.97.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The business had revenue of $345.50 million during the quarter, compared to analysts’ expectations of $342.57 million. During the same quarter in the prior year, the firm earned $0.99 EPS. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. On average, equities analysts expect that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HAE has been the topic of several recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $112.00 target price on shares of Haemonetics in a report on Tuesday, December 3rd. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective for the company in a report on Friday, November 8th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price on the stock. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Haemonetics in a research note on Wednesday, December 4th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $108.78.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.